US2022047583A1PendingUtilityA1

Product and method for treating diarrhea

66
Assignee: MAREGADE RX LLCPriority: Mar 14, 2013Filed: May 28, 2021Published: Feb 17, 2022
Est. expiryMar 14, 2033(~6.7 yrs left)· nominal 20-yr term from priority
Inventors:Reed B. Hogan, Ii
A61K 31/495A61K 31/426A61K 45/06A61P 1/12A61K 9/0053A61K 31/341A61K 9/20A61K 9/48A61K 2300/00A61K 31/4164Y02A50/30
66
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of treating diarrhea in a patient includes administering an H1 receptor antagonist and an H2 receptor antagonist to the patient.

Claims

exact text as granted — not AI-modified
1 . A method of treating diarrhea in a patient, comprising administering an H1 receptor antagonist and an H2 receptor antagonist to the patient, wherein the patient does not have mastocytic enterocolitis. 
     
     
         2 . (canceled) 
     
     
         3 . The method of  claim 1 , wherein the H1 receptor antagonist comprises cetirizine, levocetirizine, or mixtures thereof. 
     
     
         4 . The method of  claim 1 , wherein the H2 receptor antagonist comprises famotidine, ranitidine, or mixtures thereof. 
     
     
         5 . The method of  claim 1 , wherein the H1 receptor antagonist and the H2 receptor antagonist are administered simultaneously. 
     
     
         6 . The method of  claim 1 , wherein the H1 receptor antagonist and the H2 receptor antagonist are administered once per day for at least 2 days. 
     
     
         7 . The method of  claim 1 , wherein the H1 receptor antagonist and the H2 receptor antagonist are administered once per day for at least 7 days. 
     
     
         8 - 17 . (canceled) 
     
     
         18 . The method of  claim 1 , wherein the H1 receptor antagonist comprises cetirizine and the cetirizine is administered in an amount of 5 to 20 mg. 
     
     
         19 . The method of  claim 1 , wherein the H2 receptor antagonist comprises famotidine and the famotidine is administered in an amount of 10 to 40 mg. 
     
     
         20 . The method of  claim 1 , wherein the H1 receptor antagonist comprises cetirizine,
 the H2 receptor antagonist comprises famotidine, and   the famotidine and the cetirizine are administered together as a unit dosage form.   
     
     
         21 - 40 . (canceled) 
     
     
         41 . A pharmaceutical composition for treating diarrhea, comprising:
 an H1 receptor antagonist, and   an H2 receptor antagonist,   wherein the H2 receptor antagonist is not ranitidine, and   the pharmaceutical composition is an oral dosage form.   
     
     
         42 . (canceled) 
     
     
         43 . The pharmaceutical composition of  claim 41 , wherein the H1 receptor antagonist comprises cetirizine, levocetirizine, or mixtures thereof. 
     
     
         44 . The pharmaceutical composition of  claim 41 , wherein the H2 receptor antagonist comprises famotidine. 
     
     
         45 . The pharmaceutical composition of  claim 41 , wherein the H1 receptor antagonist comprises cetirizine, and the H2 receptor antagonist comprises famotidine. 
     
     
         46 . The pharmaceutical composition of  claim 41 , wherein the oral dosage form comprises a unit dosage form. 
     
     
         47 . The pharmaceutical composition of  claim 41 , wherein the oral dosage form comprises at least one tablet or capsule. 
     
     
         48 . The pharmaceutical composition of  claim 41 , wherein the oral dosage form further comprises sodium, and glucose or a glucose-containing saccharide. 
     
     
         49 . The pharmaceutical composition of  claim 41 , wherein the oral dosage form further comprises an oral rehydration solution. 
     
     
         50 . The pharmaceutical composition of  claim 41 , wherein the oral dosage form comprises a plurality of unit dosage forms. 
     
     
         51 - 80 . (canceled) 
     
     
         81 . The method of  claim 45 , wherein the cetirizine is present in an amount of 5 to 20 mg. 
     
     
         82 . The method of  claim 45 , wherein the famotidine is present in an amount of 10 to 40 mg.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.